Sandoz wins FDA nod to expand Enzeevu label to multiple retinal indications
Source: SeekingAlpha
2026-02-18 05:09:27 ET
More on Sandoz Group AG
- Sandoz: The Share Price May Have Run Its Course
- Sandoz Group AG (SDZNY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Sandoz Group AG (SDZNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Mark Cuban calls for end to generic drug application fees to boost domestic manufacturing
- Seeking Alpha’s Quant Rating on Sandoz Group AG
Read the full article on Seeking Alpha
For further details see:
Sandoz wins FDA nod to expand Enzeevu label to multiple retinal indications
Sandoz Group AG
NASDAQ: SDZNY
SDZNY Trading
-1.2% G/L:
$81.7265 Last:
15,663 Volume:
$79.46 Open:
SDZNY Latest News
September 24, 2025 04:15:00 pm
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
August 27, 2025 07:30:00 am
Sandoz welcomes Quebec government support for Boucherville plant modernization project
August 12, 2025 01:00:00 am
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
August 07, 2025 01:00:00 am
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
